Literature DB >> 15117926

Antimicrobial activity of clofazimine is not dependent on mycobacterial C-type phospholipases.

M C Bopape1, H C Steel, R Cockeran, N M Matlola, P B Fourie, R Anderson.   

Abstract

We have used a phospholipase C (PLC)-deletion mutant (plcABC) of the H37Rv strain of Mycobacterium tuberculosis (MTB), as well as a plcA-insertion mutant of Mycobacterium smegmatis, to investigate the possible involvement of PLCs in clofazimine-mediated inhibition of mycobacterial K(+) transport and growth. Inactivation of the PLCs of MTB and insertion of the plcA gene into M. smegmatis resulted in a substantial reduction and increase in hydrolysis of phosphatidylcholine (PC), respectively. However, both the mutant and wild-type strains of MTB and M. smegmatis were equally sensitive to the inhibitory effects of clofazimine on K(+) uptake and growth. These observations demonstrate that the PLCs of MTB are not involved in the antimicrobial activity of clofazimine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117926     DOI: 10.1093/jac/dkh215

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.

Authors:  Jakko van Ingen; Sarah E Totten; Niels K Helstrom; Leonid B Heifets; Martin J Boeree; Charles L Daley
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

2.  Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.

Authors:  Takahiro Yano; Sacha Kassovska-Bratinova; J Shin Teh; Jeffrey Winkler; Kevin Sullivan; Andre Isaacs; Norman M Schechter; Harvey Rubin
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

3.  Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

Authors:  Jacques H Grosset; Sandeep Tyagi; Deepak V Almeida; Paul J Converse; Si-Yang Li; Nicole C Ammerman; William R Bishai; Donald Enarson; Arnaud Trébucq
Journal:  Am J Respir Crit Care Med       Date:  2013-09-01       Impact factor: 21.405

4.  Purification and characterization of mycobacterial phospholipase A: an activity associated with mycobacterial cutinase.

Authors:  Sarah K Parker; Kathryn M Curtin; Michael L Vasil
Journal:  J Bacteriol       Date:  2007-04-06       Impact factor: 3.490

5.  Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.

Authors:  Kelly M Pennington; Ann Vu; Douglas Challener; Christina G Rivera; F N U Shweta; John D Zeuli; Zelalem Temesgen
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-05-08

6.  Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial.

Authors:  Patrick Nachipo; David Hermann; Gerald Quinnan; Melita A Gordon; Wesley C Van Voorhis; Pui-Ying Iroh Tam
Journal:  Trials       Date:  2018-08-23       Impact factor: 2.279

7.  Modeling Host-Pathogen Interaction to Elucidate the Metabolic Drug Response of Intracellular Mycobacterium tuberculosis.

Authors:  Rienk A Rienksma; Peter J Schaap; Vitor A P Martins Dos Santos; Maria Suarez-Diez
Journal:  Front Cell Infect Microbiol       Date:  2019-05-08       Impact factor: 5.293

Review 8.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.